NCT06354114尚未招募2 期
A Single-arm Open-label Phase II Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR) by Investigator
研究概览
简要总结
The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Voluntarily sign the written informed consent and willing to cooperate with the research according to the requirements of the plan.
- •2.Breast cancer confirmed by histology or cytology and meeting the following conditions:
- •According to the breast cancer diagnosis and treatment guidelines (2022) of the Chinese Society of Clinical Oncology (CSCO), the breast cancer patients who are suitable for anti-tumor treatment with paclitaxel for injection (albumin-bound) alone judged by the investigators.
- •According to RECIST 1.1 standard, there is at least one measurable lesion. For the lesions that have been treated with radiotherapy in the past, only if the disease progression is clear after radiotherapy, then the lesions can be included as the measurable lesions.
- •Age ≥ 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days before the first administration.
- •Expected survival time ≥3 months.
- •Normal function of main organs within 7 days before the first administration [no blood transfusion, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF) or other medical support treatment within 14 days before the first administration], meeting the following criteria:
- •Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelet count (PLT)≥ 100 × 10^9/L; Hemoglobin (Hb) ≥ 90 g/L.
- •AST & ALT ≤ 10 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN and Creatinine clearance ≥ 30 mL/min.
- •Activated partial thrombin time (APTT) /Prothrombin time (PT)/International standardized ratio (INR)≤1.5 × ULN.
- •The patients with fertility agreed to use reliable contraceptive measures (such as intrauterine device [IUD], contraceptives or condoms) during the study period and within 6 months after the end of the study; The serum pregnancy test of women of childbearing age is negative within 7 days before the study enrollment.
排除标准
- •History of severe allergy or major hypersensitivity to paclitaxel or human serum albumin (NCI-CTCAE Version 5.0, ≥ Level 3).
- •The toxicity of previous anti-tumor treatment has not recovered (NCI-CTC AE 5.0, >Level 1); Skin reaction or other hypersensitivity caused by any reason does not return to normal.
- •Patients with symptomatic brain metastasis or meningeal metastasis, or there is any evidence that shows uncontrolled brain metastasis or meningeal metastasis.
- •History of malignant tumors other than breast cancer within 5 years before the first administration, except for tumors that have recovered after treatment, such as carcinoma in situ, basal cell carcinoma, etc.
- •There are any of the following concomitant diseases:
- •Serious or uncontrolled cardiovascular diseases: such as chronic congestive heart failure of grade Ⅱ or above (NYHA standard), uncontrolled hypertension (systolic blood pressure>150 mmHg and/or diastolic blood pressure>90 mmHg after regular treatment), etc.
- •There are clearly identified neurological diseases (such as epilepsy, dementia, etc.) and ≥ grade 3 peripheral neuropathy.
- •Serious respiratory diseases, such as asthma requiring glucocorticoid drugs, chronic obstructive pulmonary disease (acute exacerbation), etc.
- •Uncontrolled diabetes (fasting blood glucose ≥ 10 mmol/L after regular treatment).
- •Serious chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment (such as anti-infective drugs have been used for more than one week before the first administration and will continue to be used), including tuberculosis infection, etc.
- •Active HBV (HBsAg positive patients need to be tested for HBV DNA, which will be excluded if the HBV DNA is greater than the upper limit of the normal value) or HCV infection (patients with polymerase chain reaction (PCR) HCV RNA within the normal value range can participate in this study) or syphilis antibody positive (and confirmed) or HIV positive.
- •Rash on any part of the body and any disease that may cause skin reactions, such as cholestasis, systemic lupus erythematosus, eczema, allergic dermatitis, atopic dermatitis, herpes zoster, psoriasis, etc.
- •Have the following previous medical history:
- •Major surgical operations (such as abdominal and thoracic major operations; excluding minor operations such as diagnostic puncture or infusion device implantation) have been performed within 28 days before the first administration of the study treatment, or major surgical treatment is expected to be required during the study period.
- •Serious cardio-cerebrovascular diseases occurred within 6 months before the first administration, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident (lacunar cerebral infarction without clinical significance can be included), etc.
- •The following previous/concomitant drugs or therapies exist:
- •Those who use glucocorticoids or antihistamines or other drugs with therapeutic or preventive effects on rash within 2 weeks or 5 half-lives (whichever is longer) before the first administration.
- •Use of chemical small molecule antitumor drugs (including endocrine therapy) within 2 weeks or use of biological macromolecule anti-tumor, biological therapy, radiotherapy within 4 weeks before the first administration. Those who need to be treated with other anti-tumor drugs during the study.
- •Vaccinated within 4 weeks before the first administration or expected to be vaccinated during the observation period of study administration.
- •Those who are expected to undergo radiotherapy or hemodialysis within 2 months after the first administration.
- •Patients who are pregnant, nursing or planning to become pregnant during the study.
- •Other situations in which the investigator judged that the patient was not suitable for the study.
研究组 & 干预措施
SYHX2011
Experimental
Subjects will be administrated with SYHX2011 once every 3 weeks.
干预措施: SYHX2011 (Drug)
结局指标
主要结局
Objective Response Rate (ORR) by Investigator
时间窗: *Time Frame: Up to approximately 2 years
次要结局
- Progression-Free-Survival (PFS)(Up to approximately 2 years)
- Time to progression (TTP)(Up to approximately 2 years)
- Incidence of adverse events(Up to approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Endostar + GT in Pulmonary Metastases of Soft Tissue SarcomaSoft Tissue SarcomaNCT01812018Peng Yuan30
已完成
2 期
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaHCCNCT04542837Peking University Cancer Hospital & Institute55
进行中（未招募）
2 期
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Non-Small Cell Lung CancerNCT06606847AstraZeneca30
已完成
2 期
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic SyndromeAcute Myeloid LeukemiaNCT03824080GWT-TUD GmbH45
招募中
2 期
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerHER-2 Negative Breast CancerNCT05398861Henan Cancer Hospital79